Search
for
Sort by
Research 121–150 of 474
- AIRE Deficiency Leads to the Development of Alopecia Areata‒Like Lesions in Mice
- Conserved γδ T cell selection by BTNL proteins limits progression of human inflammatory bowel disease
- Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges – A Narrative Review
- Cellular plasticity in reprogramming, rejuvenation and tumorigenesis: a pioneer TF perspective
- Enhancing Cancer Therapy with Hyperthermia: Synergistic Effects with Natural Compounds and Conventional Treatments
- Alopecia Areata: A Review of the Role of Oxidative Stress, Possible Biomarkers, and Potential Novel Therapeutic Approaches
- Intestinal Intraepithelial Lymphocytes: Sentinels of the Mucosal Barrier
- Natural killer cells in atopic and autoimmune diseases of the skin
- The regenerative potential of skin and the immune system
- Regenerative Medicine-Based Treatment for Vitiligo: An Overview
- Hair Growth Effect of Emulsion Extracted Brevilin A, a JAK3 Inhibitor, from Centipeda minima
- Regulatory T cells in skin regeneration and wound healing
- Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling
- Pyroptosis in Alopecia Areata: Synthesizing Emerging Hypotheses and Charting a Path to New Therapies
- Pathogenesis and regenerative therapy in vitiligo and alopecia areata: focus on hair follicle
- Astilbin Activates the Reactive Oxidative Species/PPARγ Pathway to Suppress Effector CD4+ T Cell Activities via Direct Binding With Cytochrome P450 1B1
- Review of Promising Off-Label Use of Deucravacitinib
- Associations between ionomic profile and metabolic abnormalities in a murine model of sodium sulfide induced alopecia areata
- Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Role of janus kinase inhibitors in the treatment of alopecia areata
- Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
- Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
- Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans
- SOCS3 treatment prevents the development of alopecia areata by inhibiting CD8+ T cell-mediated autoimmune destruction
- Diverse Role of OX40 on T Cells as a Therapeutic Target for Skin Diseases
- Deciphering the Complex Immunopathogenesis of Alopecia Areata